Skip to main content
. 2020 Nov 20;20:23–33. doi: 10.1016/j.omto.2020.11.003

Figure 2.

Figure 2

Characterization of the antisarcoma effect of the HCA-EFZP-IL-12 vector

Sarcoma-bearing mice were treated as described in Figure 1 and sacrificed on day 80. (A) Differences in tumor growth shown as percentages in comparison with the control groups. (B) Analyses of tumor burden development in the saline (control group) and HCA-EFZP-IL-12-treated (HCA-IL-12) groups. Tumor volume in the mouse tibias was measured on different days until the end of the experiment. (C) Survival curves. Graphs represent the overall survival of mice treated with HCA-EFZP-IL-12 (gray line) or PBS (black line). (D) Representative macroscopic images and H&E-stained sections of tibias from PBS- or HCA-EFZP-IL-12-treated mice.